A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder.

Trial Profile

A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2012

At a glance

  • Drugs Imagabalin (Primary) ; Paroxetine
  • Indications Generalised anxiety disorder
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Nov 2012 Planned number of patients changed from 287 to 528.
    • 10 Jul 2009 Planned end date changed from 1 Mar 2009 to 1 Apr 2009 as reported by ClinicalTrials.gov.
    • 09 Mar 2009 Planned number of patients changed from 528 to 287 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top